my today's an to private-end joining help the accomplishments second value-driving initiatives and Thank occurred On and thanks groundwork everyone and I'll these this provide Andrew, XXXX that strategy changes of how morning. XXXX the us lay Yes. during ] in you, part and overview for of [ many our call, beyond.
tremendous some remarks. that financial have us upon. on I XXXX already Fred we will Starting follow Additionally, our will and after customer-facing first update, advancing to structure and of progress to had areas, questions all R&D both then XXXX. on assuming the CFO, significant including: we the quarter and have will June with made improving first, sheet; across services business right of provide prepared answer to the touch and support be our controlling successes a second, Leffler, with our our in discussion results, customers; initiatives and Ameluz, X clinical balance our starting available critical third, cost our teams optimizing
price license X very million, of will to June group another development, year. take Germany, proceeds be we Ameluz for support employees all I finance Biofrontera would buy we has as as the progress revenue to Group in Biofrontera and comment for in from for and financing supply dramatic reduction transfer reductions in record Ameluz which, for our net $XX.X ongoing further German a commercial our activities announced of clinical XXXX. and million tranche of million the the following XX% a recently organization like over QX. we increase mentioned, of tremendous -- with investors paid and our in renegotiation been will This by expect These secured agreement X we the the realized used to Biofrontera
at have placed during number share installed to our up highest of we are most lamps increase the While placed that and an for revenue, we proud were compared also to the XX% ever offices makes XXX physician a XXXX, in in year XX of year. Ameluz BF-RhodoLED single
and are field set lamp and growing to of Ameluz-PDT PDT, future future among a and additional indicator growth place lamps with The both for are installations remaining the XX for an XXX diseases. of treatment in familiar to installations, now least effective delighted new PDT. patients. and Lamp Ameluz-PDT already more recognition provide through had Ameluz Ameluz the More and lamps with dermatology sites up first-time offices of are other number growth, practices keratonosis actinic in already lamps facilitating The as the we customers. to patient-friendly placements existing one XX reflects and the at BF-RhodoLED in a bought start increasing specifically, of our their leading further also
During reduced a support and teams. our in XXXX, invested and structure cost we of the have cost commercial our proportion savings
invest support. to reimbursement and continuing strategic are focused in We to by resources medical optimize from strategy force accounts, our organization shifting a marketing, sales customer-facing
in financially will allowed dispute December, treatment by unproblematic and a patient bill XEPI then moment. this to sales and the the into balance our doing regarding Increasing the will in This further asset. approach territory to from By buy-in stakeholders To a relates settled to be better Ameluz to around our will significant we that We we remove doctor's explain, process continuing be team to our efficient. all supports our to acquisition the purchases this make believe bringing offices, arbitration efforts supporting of within office. more suited in need managers bill viable PDT us organizations. which new develop help growth our force PDT. customers buy-in to are training a market liabilities reimbursement so, discuss which customer Fred In sheet,
developments, development research and patents. Now turning new to and
XXXX impact expect We commercial that business. X developments for significant our favorably will
Rhodo-LED areas year. extended We of QX skin AK are the damaged launch XL lamp in the of larger for planning photo to with treatment this
for and completed, was was the review. tubes to allows study While skin area, data FDA this illumination and safety submitted a larger the by of X a accepted
of larger of constituting this Lamp, for into our include per XXXX. treatment will to with up Administration, of glycol allow tubes X PDT use Ameluz of XL We Food expect the during The a and the of treatment label the the formulation keratosis. QX skin In U.S. a combination lacking to requirement for areas, new the the of approved propylene actinic further has FDA, Ameluz Drug crucial launch growth.
related with impurities We patients life. XXXX of expect which an Office, generation that in granted U.S. and our expected but conventional PDT formulation extend the patents affected time, The Rhodo-LED reducing result currently [ or ] for painful, and in granted currently tolerability is less patent protection over protected a the U.S. photodynamic be therapy Further a production while extended further. until will even patents the Trademark XXXX begin office, effective Ameluz PTO, help some patents all of or that this shelf XXXX. and of Patent our protocol may our to patent the U.S. and improve to to similarly PDT. PDT until is are of Between still also may new by pending
expect looking started Ameluz photodynamic prototype begin additional The XXXX, building lamps the process In with lamps. XXXX, --in next X we use steps portable near a for we patents therapy at we for planning in we completion, of to these development for low-cost is nearing future. and purchased and sorry, purchased
Germany to is Phase suffer the only patient This successful not on direct and randomized, months renegotiation extremities, with supply XL scalp but neck III, keratosis and Biofrontera and tongue. of patients transformational of efficacy the up to for license studies and announce the areas on and the field Ameluz that securing has body. group subsequent e of RhodoLED various on the We seen for a are a many our dosed developments and multicenter million in also also in of the last the our our first actinic company been LSA, clinical X double-blind vehicle-controlled a agreement with opportunity safety lamps Ameluz for AK face from evaluate of financing. to treatment RhodoLED exposed as in $XX and the their significant company The our pleased have in
XXXX only to applies will Ameluz and price. a a amount flat revenues any cancers, from million to up and reduced step LSA, 'XX This then to however, years. have skin pay while It secured indications. related keratosis XX% non-melanoma up amended in flat to of the step-wise, million to million and XX and we XX% XX% XX% 'XX. to from licenser actinic XX% is According our to for XX our structure, in we price XX% for our This the up XX acne have we to indefinitely transfer subsequent
This price. control of savings effectively allows portion amendment, all XXXX. As is be run expected from their trials to The clinical additional costs. is trials a cost over of and X, the taking to us of as reduced these this the Inc. transfer only part June more Biofrontera arrangement
In separate that closed funding up closed have secured is this paid we Finally, deals. in XX we of X on financing November X to for XXXX, million expected tranches. company sufficient to placement be we of a in on of million. the February And $X.X year, additional private for
Fred? the We more or forward that, full to turn meet Fred programs fourth through the We on have to additional With received either call requirements call. June the first our $X $X million XXXX. these and to expect to tranche walk to all and and updates of quarter look details the over May on year. providing in million XXXX I'll financial secure the quarter
